Biotech

All Articles

Neurocrine's KarXT opponent hits in stage 2-- yet just at low dosage

.Neurocrine Biosciences has actually achieved its own hoped-for profile page in a stage 2 schizophre...

Vaderis' rare capillary condition medication minimizes nosebleeds

.Vaderis Rehabs' objective to develop the very first medicine striven specifically at a specific rar...

Navigator increases $100M to develop brand-new autoimmune pipeline

.Sat nav Medicines has furnished itself with $100 million in series A funds as the youthful biotech ...

Duality seeks money for ADC trials as IPO surge spreads to Asia

.China's Duplicity Biotherapeutics has filed (PDF) paperwork for a Hong Kong IPO, seeking an undiscl...

YolTech markets China liberties to gene editing therapy for $29M

.4 months after Chinese genetics editing business YolTech Therapies took its cholesterol disease-foc...

Addex sell increases after Indivior provides to $300M for material

.Indivior is actually getting a little particle allosteric modulator tailored to manage substance us...

Molecular Partners modifies AML test over 'suboptimal direct exposure'

.Molecular Companions has identified "suboptimal visibility" to its tetra-specific T-cell engager as...

Despite combined market, a venture capital rebirth could be can be found in Europe: PitchBook

.While the biotech expenditure performance in Europe has reduced quite adhering to a COVID-19 financ...

8 months after a $213M fundraise, gene publisher Volume produces cuts

.After increasing $213 million in 2023-- among the year's most extensive personal biotech shots-- To...

BioMarin develops director crew with biotech veterinarians-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, shootings...